ALT Ishares Diversified Alternatives Trust

In the news release, Alteon (AMEX:ALT) Provides Corporate Update, issued earlier today by Alteon Inc. over PR Newswire, we are advised by the company that the first bullet point should be disregarded as it contained erroneous information. The complete, corrected first bullet follows: * Alteon plans to pursue development of lead compound alagebrium in high potential cardiovascular indications such as heart failure, after recent data presented at the American Heart Association (AHA) Scientific Sessions in November 2005 demonstrated continued positive results of alagebrium in patients with cardiovascular disease. The AHA presentations included data from the Phase 2a PEDESTAL study in diastolic dysfunction in heart failure with impaired ejection fraction, as well as positive results from a Phase 2a study in endothelial function. Alteon is in the process of preparing an IND specifically in heart failure in order to expand its clinical program in this therapeutic area. Any continued development of alagebrium by the Company is contingent upon Alteon entering into strategic collaboration agreements for this product candidate which, among other things, would be required to include funding for product development. PRNewswire -- Feb. 1 DATASOURCE: Alteon Inc.

Copyright